Ragweed sublingual immunotherapy tablets improve ragweed allergic rhinitis symptoms in children, according to new research.
In this international double-blind placebo-controlled trial, researchers randomly assigned polysensitized children (N=1025) aged 5 to 17 years with ragweed allergic rhinitis (with or without conjunctivitis) and with or without asthma (forced expiratory volume in 1 second ≥80% predicted) to receive a daily ragweed SLIT tablet (12 Amb a 1-unit dose) or placebo for <28 weeks (ClinicalTrials.gov Identifier: NCT02478398).
The primary end point was the average total combined score (sum of rhinoconjunctivitis daily symptom score and daily medication score) during peak ragweed season. Secondary end points included average total combined score during the entire ragweed season, as well as the daily symptom and daily medication scores during peak season.
